Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI claim matches the FDA label stewardship/appropriate-use language in Indications and Usage and the Precautions (General) section, with no contradictions.
Category Scores
Accurate Statements
Clarithromycin extended-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Supported by Section 1 (Indications and Usage): “...clarithromycin extended-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.” Also supported by Section 5 (Precautions → General): “Prescribing clarithromycin extended-release tablets in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.”
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The statement promotes on-label appropriate use consistent with the label’s direction to reserve therapy for proven or strongly suspected susceptible bacterial infections and discourages use without such an indication.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement